The Food and Drug Administration (FDA) has initiated a Class II drug recall for Semaglutide Inj (NDC 84223-001-07) manufactured by New Life Pharma LLC. The recall is due to a lack of assurance of sterility and impacts product distributed in Ohio.

This recall signifies a critical product quality issue that requires immediate attention from any entities involved in the distribution or handling of this specific Semaglutide Inj product. While the document does not specify a compliance deadline, the nature of a sterility issue necessitates prompt action to remove the product from circulation to prevent potential patient harm. Companies should review their inventory and distribution records for affected lots and coordinate with New Life Pharma and the FDA regarding disposition and reporting.